Tazobactam (BioDeep_00000006599)

 

Secondary id: BioDeep_00001868359

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds


代谢物信息卡片


(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

化学式: C10H12N4O5S (300.0528382)
中文名称: 他唑巴坦酸, 他唑巴坦
谱图信息: 最多检出来源 Homo sapiens(blood) 0.84%

分子结构信息

SMILES: CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
InChI: InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1

描述信息

Tazobactam is only found in individuals that have used or taken this drug.It is a antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases.Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade piperacillin.
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CG - Beta-lactamase inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D065093 - beta-Lactamase Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C2140 - Adjuvant > C183118 - Beta-lactamase Inhibitor
D004791 - Enzyme Inhibitors
Tazobactam (CL-298741) is a potent β-lactamases inhibitor and penicillin antibiotic. Tazobactam has antibacterial activity. Tazobactam can be used for pneumonia research[1][2].

同义名列表

14 个代谢物同义名

(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4λ⁶-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide; Taszobactam sodium; Tazobactam sodium; SCHEMBL13437219; Tazobactamum; Tazobactam; YTR 830H; YTR 830; YTR-830; CL-298741; YTR-830H; Tazobactam



数据库引用编号

21 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Robert Strengen Bigseth, Håkon Sandholdt, Andreas Petersen, Christian Østergaard, Thomas Benfield, Louise Thorlacius-Ussing. Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia. Microbiology spectrum. 2022 06; 10(3):e0153021. doi: 10.1128/spectrum.01530-21. [PMID: 35438533]
  • Hiie Soeorg, Aveli Noortoots, Maarja Karu, Kadri Saks, Jana Lass, Irja Lutsar, Lenne-Triin Kõrgvee. Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients. European journal of clinical pharmacology. 2022 Jun; 78(6):989-1001. doi: 10.1007/s00228-022-03307-0. [PMID: 35275224]
  • Eveline Wallenburg, Rob Ter Heine, Jeroen A Schouten, Jelmer Raaijmakers, Jaap Ten Oever, Eva Kolwijck, David M Burger, Peter Pickkers, Tim Frenzel, Roger J M Brüggemann. An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. Clinical pharmacokinetics. 2022 06; 61(6):907-918. doi: 10.1007/s40262-022-01113-6. [PMID: 35377133]
  • Wei Gao, Julie Passarell, Yogesh T Patel, Zufei Zhang, Gina Lin, Jill Fiedler-Kelly, Christopher J Bruno, Elizabeth G Rhee, Carisa S De Anda, Hwa-Ping Feng. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP. Antimicrobial agents and chemotherapy. 2022 05; 66(5):e0139921. doi: 10.1128/aac.01399-21. [PMID: 35471040]
  • Yong Kyun Kim, Hyoung Soo Kim, Sunghoon Park, Hwan-Il Kim, Sun Hee Lee, Dong-Hwan Lee. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. The Journal of antimicrobial chemotherapy. 2022 04; 77(5):1353-1364. doi: 10.1093/jac/dkac059. [PMID: 35224630]
  • Nezar M Bahabri, Maha Mahmoud Al-Alawi, Mohammed O Qutub, Wail A Tashkandi, Raha AlTurki, Safiah Saad Janah, Heidi Essam Ali, Albandari F Almutairi, Sherif Khalil. In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals. Journal of infection and public health. 2022 Apr; 15(4):486-490. doi: 10.1016/j.jiph.2022.02.009. [PMID: 35221238]
  • Bence Mogyoródi, András B Csékó, Csaba Hermann, János Gál, Zsolt D Iványi. Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa. Scientific reports. 2022 03; 12(1):4455. doi: 10.1038/s41598-022-08307-9. [PMID: 35292686]
  • Thamer A Almangour, Ahmad Aljabri, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Nader Damfu, Awaly Alfozan, Basem M Alraddadi, Majda Alattas, Mohammed Qutub, Abrar F Alhameed, Malik Khuwaja, Ahlam Alghamdi, Khalifa M Binkhamis, Wafa Alfahad, Fatimah S AlShahrani. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. Journal of global antimicrobial resistance. 2022 03; 28(?):288-294. doi: 10.1016/j.jgar.2022.01.023. [PMID: 35121161]
  • Sunish Shah, Derek N Bremmer, Ellen G Kline, David P Nicolau, Ryan K Shields. Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2022 Jan; 28(1):87-90. doi: 10.1016/j.jiac.2021.08.013. [PMID: 34535403]
  • Chi-Hao Shao, Chih-Hsun Tai, Fang-Ju Lin, Chien-Chih Wu, Jann-Tay Wang, Chi-Chuan Wang. Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam. Journal of the Formosan Medical Association = Taiwan yi zhi. 2022 Jan; 121(1 Pt 1):117-125. doi: 10.1016/j.jfma.2021.02.004. [PMID: 33637370]
  • Jongsung Hahn, Kyoung Lok Min, Soyoung Kang, Seungwon Yang, Min Soo Park, Jin Wi, Min Jung Chang. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Microbiology spectrum. 2021 12; 9(3):e0063321. doi: 10.1128/spectrum.00633-21. [PMID: 34937189]
  • Vesa Cheng, Mohd H Abdul-Aziz, Fay Burrows, Hergen Buscher, Young-Jae Cho, Amanda Corley, Arne Diehl, Eileen Gilder, Stephan M Jakob, Hyung-Sook Kim, Bianca J Levkovich, Sung Yoon Lim, Shay McGuinness, Rachael Parke, Vincent Pellegrino, Yok-Ai Que, Claire Reynolds, Sam Rudham, Steven C Wallis, Susan A Welch, David Zacharias, John F Fraser, Kiran Shekar, Jason A Roberts. Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. Antimicrobial agents and chemotherapy. 2021 10; 65(11):e0143821. doi: 10.1128/aac.01438-21. [PMID: 34460303]
  • Andrew F Shorr, Christopher J Bruno, Zufei Zhang, Erin Jensen, Wei Gao, Hwa-Ping Feng, Jennifer A Huntington, Brian Yu, Elizabeth G Rhee, Carisa De Anda, Sumit Basu, Marin H Kollef. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Critical care (London, England). 2021 10; 25(1):354. doi: 10.1186/s13054-021-03773-5. [PMID: 34600585]
  • A Pinilla-Rello, R Huarte-Lacunza, A Magallón-Martínez, L Cazorla-Poderoso, O Pereira-Blanco, M Pérez-Moreno, I Larrodé-Leciñena, R M Martínez-Álvarez, A I López-Calleja. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2021 Oct; 34(5):441-449. doi: 10.37201/req/006.2021. [PMID: 34154319]
  • Sarah Van Vooren, Jan J De Waele, Jerina Boelens, Michael Polet, Veronique Stove, Lynn Vanhaecke, Alain G Verstraete. Development and validation of a liquid chromatography high-resolution mass spectrometry orbitrap method for the sensitive quantification of amoxicillin, piperacillin, tazobactam and meropenem in human faeces. Analytica chimica acta. 2021 Sep; 1177(?):338760. doi: 10.1016/j.aca.2021.338760. [PMID: 34482897]
  • Neena Kanwar, Dithi Banerjee, Christopher J Harrison, Jason G Newland, Xuan Qin, Danielle M Zerr, Theoklis Zaoutis, Rangaraj Selvarangan. Comparative in vitro effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates. Journal of chemotherapy (Florence, Italy). 2021 Sep; 33(5):288-293. doi: 10.1080/1120009x.2021.1888030. [PMID: 33645447]
  • Matthew W Bjergum, Erin F Barreto, Marc H Scheetz, Andrew D Rule, Paul J Jannetto. Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. The journal of applied laboratory medicine. 2021 09; 6(5):1202-1212. doi: 10.1093/jalm/jfab036. [PMID: 34086904]
  • V Al Jalali, M Wölfl-Duchek, M Taubert, P Matzneller, E Lackner, C Dorn, A Kratzer, B Wulkersdorfer, Z Österreicher, M Zeitlinger. Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study. The Journal of antimicrobial chemotherapy. 2021 08; 76(9):2342-2351. doi: 10.1093/jac/dkab166. [PMID: 34050650]
  • Sofie Rutjens, Siska Croubels, Siegrid De Baere, Mathias Devreese. Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Methods for the Quantification of Cefquinome, Ceftiofur, and Desfuroylceftiofuracetamide in Porcine Feces with Emphasis on Analyte Stability. Molecules (Basel, Switzerland). 2021 Jul; 26(15):. doi: 10.3390/molecules26154598. [PMID: 34361749]
  • Dušan Krnáč, Katarína Reiffová, Boris Rolinski. A new HPLC-MS/MS analytical method for quantification of tazobactam, piperacillin, and meropenem in human plasma. Journal of separation science. 2021 Jul; 44(14):2744-2753. doi: 10.1002/jssc.202100067. [PMID: 33988308]
  • Marianna Meschiari, Iacopo Franconi, Erica Bacca, Vincenzo Bianco, Gabriella Orlando, Gianluca Cuomo, Andrea Bedini, Cristina Mussini. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection. 2021 Jun; 49(3):549-553. doi: 10.1007/s15010-020-01539-9. [PMID: 33074365]
  • Suzanne L Parker, Saurabh Pandey, Fekade B Sime, Janine Stuart, Jeffrey Lipman, Jason A Roberts, Steven C Wallis. A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Clinical chemistry and laboratory medicine. 2021 04; 59(5):921-933. doi: 10.1515/cclm-2020-1196. [PMID: 33554515]
  • David P Nicolau, Jan De Waele, Joseph L Kuti, Luzelena Caro, Kajal B Larson, Brian Yu, Elaine Gadzicki, Zhen Zeng, Elizabeth G Rhee, Matthew L Rizk. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International journal of antimicrobial agents. 2021 Apr; 57(4):106299. doi: 10.1016/j.ijantimicag.2021.106299. [PMID: 33567333]
  • S Alexander Winans, Richelle L Guerrero-Wooley, Susie H Park, Garret Hino, Steven C Forland. Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis. Infection. 2021 Apr; 49(2):355-359. doi: 10.1007/s15010-020-01510-8. [PMID: 32862306]
  • Christian M Gill, Kamilia Abdelraouf, David P Nicolau. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. The Journal of antimicrobial chemotherapy. 2021 03; 76(4):993-1000. doi: 10.1093/jac/dkaa551. [PMID: 33438033]
  • Zana Rubic, Silvija Soprek, Marko Jelic, Anita Novak, Ivana Goic-Barisic, Marina Radic, Arjana Tambic-Andrasevic, Marija Tonkic. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant Proteus mirabilis in a University Hospital of Split, Croatia. Microbial drug resistance (Larchmont, N.Y.). 2021 Feb; 27(2):162-169. doi: 10.1089/mdr.2020.0002. [PMID: 32429775]
  • Zufei Zhang, Yogesh T Patel, Jill Fiedler-Kelly, Hwa-Ping Feng, Christopher J Bruno, Wei Gao. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia. Journal of clinical pharmacology. 2021 02; 61(2):254-268. doi: 10.1002/jcph.1733. [PMID: 32949031]
  • Fekade B Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L Parker, Steven C Wallis, Jeffrey Lipman, Jason A Roberts. Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. Antimicrobial agents and chemotherapy. 2020 12; 65(1):. doi: 10.1128/aac.01698-20. [PMID: 33077655]
  • William C Putnam, Raja Reddy Kallem, Vindhya Edpuganti, Indhu Subramaniyan, Ronald G Hall. Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Nov; 1159(?):122354. doi: 10.1016/j.jchromb.2020.122354. [PMID: 32905989]
  • Jennifer A Huntington, Brian Yu, Linping Li, Erin Jensen, Christopher Bruno, Mathew Boakye, Zufei Zhang, Wei Gao, Hwa-Ping Feng, Elizabeth Rhee. Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP). Antimicrobial agents and chemotherapy. 2020 11; 64(12):. doi: 10.1128/aac.00731-20. [PMID: 32988827]
  • Irene Galani, Vassiliki Papoutsaki, Irene Karantani, Ilias Karaiskos, Lamprini Galani, Panagiota Adamou, Ioannis Deliolanis, Antigoni Kodonaki, Eleni Papadogeorgaki, Margarita Markopoulou, Sofia Maraki, Maria Damala, Eleni Prifti, Eleni Vagiakou, Efthimia Petinaki, Kimon Fountoulis, Sophia Tsiplakou, Helen Kirikou, Maria Souli, Anastasia Antoniadou, Helen Giamarellou. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. The Journal of antimicrobial chemotherapy. 2020 08; 75(8):2164-2172. doi: 10.1093/jac/dkaa160. [PMID: 32449909]
  • Antonio C Arrieta, Jocelyn Y Ang, Zufei Zhang, Kajal B Larson, Brian Yu, Matthew G Johnson, Elizabeth G Rhee, Ed H Feng, Matthew L Rizk. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Pediatric pulmonology. 2020 08; 55(8):2025-2032. doi: 10.1002/ppul.24815. [PMID: 32421928]
  • Jason M Pogue, Keith S Kaye, Michael P Veve, Twisha S Patel, Anthony T Gerlach, Susan L Davis, Laura A Puzniak, Tom M File, Shannon Olson, Sorabh Dhar, Robert A Bonomo, Federico Perez. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 07; 71(2):304-310. doi: 10.1093/cid/ciz816. [PMID: 31545346]
  • Luzelena Caro, David P Nicolau, Jan J De Waele, Joseph L Kuti, Kajal B Larson, Elaine Gadzicki, Brian Yu, Zhen Zeng, Adedayo Adedoyin, Elizabeth G Rhee. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. The Journal of antimicrobial chemotherapy. 2020 06; 75(6):1546-1553. doi: 10.1093/jac/dkaa049. [PMID: 32211756]
  • A R Buonomo, A E Maraolo, R Scotto, M Foggia, E Zappulo, P Congera, S Parente, I Gentile. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. Infection. 2020 Apr; 48(2):303-307. doi: 10.1007/s15010-020-01390-y. [PMID: 31981091]
  • Sarah C J Jorgensen, Trang D Trinh, Evan J Zasowski, Abdalhamid M Lagnf, Samuel P Simon, Sahil Bhatia, Sarah M Melvin, Molly E Steed, Natalie A Finch, Taylor Morrisette, Sandy J Estrada, Joshua R Rosenberg, Susan L Davis, Michael J Rybak. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrobial agents and chemotherapy. 2020 03; 64(4):. doi: 10.1128/aac.02291-19. [PMID: 31932379]
  • Hasan Cenk Mirza, Elvan Hortaç, Aylin Altay Koçak, M Hamiyet Demirkaya, Buket Yayla, Aylin Üsküdar Güçlü, Ahmet Başustaoğlu. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study. Journal of global antimicrobial resistance. 2020 03; 20(?):334-338. doi: 10.1016/j.jgar.2019.09.016. [PMID: 31568882]
  • Alina Karoline Nussbaumer-Pröll, Sabine Eberl, Birgit Reiter, Thomas Stimpfl, Christoph Dorn, Markus Zeitlinger. Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections. The Journal of antimicrobial chemotherapy. 2020 03; 75(3):593-599. doi: 10.1093/jac/dkz488. [PMID: 31794023]
  • Tiziana Ciarambino, Orazio Valerio Giannico, Amalia Campanile, Paolo Tirelli, Ombretta Para, Giuseppe Signoriello, Mauro Giordano. Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review. Internal and emergency medicine. 2020 03; 15(2):327-331. doi: 10.1007/s11739-020-02287-2. [PMID: 32040830]
  • Sümeyye Akyüz, Mehmet Parlak, Hüseyin Güdücüoğlu. [In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients]. Mikrobiyoloji bulteni. 2020 Jan; 54(1):154-162. doi: 10.5578/mb.68981. [PMID: 32050886]
  • Fekade B Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L Parker, Steven C Wallis, Jeffrey Lipman, Jason A Roberts. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Antimicrobial agents and chemotherapy. 2019 12; 64(1):. doi: 10.1128/aac.01655-19. [PMID: 31658965]
  • Fekade B Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L Parker, Steven C Wallis, Jeffrey Lipman, Jason A Roberts. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrobial agents and chemotherapy. 2019 10; 63(10):. doi: 10.1128/aac.01265-19. [PMID: 31358583]
  • Richard A Preston, Grigor Mamikonyan, Mushtaque Mastim, Dyal Garg, Christopher J Kemper, Allan Xu, Ravindra Yeole, Rajesh Chavan, H David Friedland, Ashima Bhatia. Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment. Antimicrobial agents and chemotherapy. 2019 10; 63(10):. doi: 10.1128/aac.00873-19. [PMID: 31332068]
  • Vidmantas Petraitis, Ruta Petraitiene, Ethan Naing, Thein Aung, Wai Phyo Thi, Povilas Kavaliauskas, Bo Bo Win Maung, Adam O Michel, Rodolfo J Ricart Arbona, Andrew C DeRyke, Darren L Culshaw, David P Nicolau, Michael J Satlin, Thomas J Walsh. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Antimicrobial agents and chemotherapy. 2019 09; 63(9):. doi: 10.1128/aac.00344-19. [PMID: 31235620]
  • Yao-Ling Wang, Sha Liu, Zhu-Jun Yu, Yuan Lei, Meng-Yi Huang, Yu-Hang Yan, Qiang Ma, Yang Zheng, Hui Deng, Ying Sun, Chengyong Wu, Yamei Yu, Qiang Chen, Zhenling Wang, Yong Wu, Guo-Bo Li. Structure-Based Development of (1-(3'-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-β-lactamases. Journal of medicinal chemistry. 2019 08; 62(15):7160-7184. doi: 10.1021/acs.jmedchem.9b00735. [PMID: 31269398]
  • Benoît Pilmis, Grégoire Petitjean, Philippe Lesprit, Matthieu Lafaurie, Najoua El Helali, Alban Le Monnier. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019 Aug; 38(8):1457-1461. doi: 10.1007/s10096-019-03573-4. [PMID: 31073653]
  • Janni S Mortensen, Berit P Jensen, Mei Zhang, Matthew Doogue. Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic drug monitoring. 2019 08; 41(4):538-543. doi: 10.1097/ftd.0000000000000650. [PMID: 31306394]
  • Henry T Quach, Adam J Esbenshade, Zhiguo Zhao, Ritu Banerjee. Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime. Pediatric blood & cancer. 2019 07; 66(7):e27750. doi: 10.1002/pbc.27750. [PMID: 30989780]
  • Kajal B Larson, Yogesh T Patel, Susan Willavize, John S Bradley, Elizabeth G Rhee, Luzelena Caro, Matthew L Rizk. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. Antimicrobial agents and chemotherapy. 2019 06; 63(6):. doi: 10.1128/aac.02578-18. [PMID: 30962340]
  • Adam M Blevins, Jennifer N Lashinsky, Craig McCammon, Marin Kollef, Scott Micek, Paul Juang. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. Antimicrobial agents and chemotherapy. 2019 05; 63(5):. doi: 10.1128/aac.02658-18. [PMID: 30782987]
  • Elaine Chan, Alan K L Wu, Cindy W S Tse, Susanna K P Lau, Patrick C Y Woo. In vitro susceptibility of Salmonella enterica serovar Typhi to ceftolozane/tazobactam. The Journal of antimicrobial chemotherapy. 2019 02; 74(2):528-530. doi: 10.1093/jac/dky418. [PMID: 30295743]
  • Soichi Arakawa, Kazuya Kawahara, Motoshi Kawahara, Mitsuru Yasuda, Go Fujimoto, Asako Sato, Ruriko Yokokawa, Tomoko Yoshinari, Elizabeth G Rhee, Norihiro Aoyama. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2019 Feb; 25(2):104-110. doi: 10.1016/j.jiac.2018.10.009. [PMID: 30420153]
  • Agathe Béranger, Sihem Benaboud, Saïk Urien, Florence Moulin, Emmanuelle Bille, Fabrice Lesage, Yi Zheng, Mathieu Genuini, Inès Gana, Sylvain Renolleau, Déborah Hirt, Jean-Marc Tréluyer, Mehdi Oualha. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Clinical pharmacokinetics. 2019 02; 58(2):223-233. doi: 10.1007/s40262-018-0682-1. [PMID: 29862466]
  • Alexander Kratzer, Selina Schießer, Peter Matzneller, Beatrix Wulkersdorfer, Markus Zeitlinger, Jens Schlossmann, Frieder Kees, Christoph Dorn. Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. Journal of pharmaceutical and biomedical analysis. 2019 Jan; 163(?):34-38. doi: 10.1016/j.jpba.2018.09.044. [PMID: 30278324]
  • Olga Saran, Beata Sulik-Tyszka, Grzegorz W Basak, Marta M Wróblewska. Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland. Medical science monitor : international medical journal of experimental and clinical research. 2019 Jan; 25(?):305-311. doi: 10.12659/msm.913352. [PMID: 30628586]
  • Raúl Rigo-Bonnin, Joan Gomez-Junyent, Laura García-Tejada, Eva Benavent, Laura Soldevila, Fe Tubau, Oscar Murillo. Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS/MS. Clinical application in the management of difficult-to-treat osteoarticular infections. Clinica chimica acta; international journal of clinical chemistry. 2019 Jan; 488(?):50-60. doi: 10.1016/j.cca.2018.10.034. [PMID: 30385280]
  • Masaya Murakami, Hiroshi Kiyota, Kanako Kasai, Shigehiro Bando, Shinichiro Kira, Haruhisa Koide, Hiroki Yamada, Takahiro Kimura, Shin Egawa. Antimicrobial prophylaxis for transurethral resection of bladder tumor: A retrospective comparison of preoperative single-dose administration of piperacillin and tazobactam/piperacillin. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2018 Dec; 24(12):954-957. doi: 10.1016/j.jiac.2018.08.008. [PMID: 30193786]
  • Monique R Bidell, Thomas P Lodise. Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings. Pharmacotherapy. 2018 12; 38(12):1205-1215. doi: 10.1002/phar.2184. [PMID: 30289995]
  • Amy D Robertson, Chenghui Li, Drayton A Hammond, Tiffany A Dickey. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem. Pharmacotherapy. 2018 12; 38(12):1184-1193. doi: 10.1002/phar.2179. [PMID: 30175410]
  • John S Bradley, Jocelyn Y Ang, Antonio C Arrieta, Kajal B Larson, Matthew L Rizk, Luzelena Caro, Shan Yang, Brian Yu, Matthew G Johnson, Elizabeth G Rhee. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. The Pediatric infectious disease journal. 2018 11; 37(11):1130-1136. doi: 10.1097/inf.0000000000002170. [PMID: 30153232]
  • Joseph Carreno, Tori Smiraglia, Christopher Hunter, Ellis Tobin, Ben Lomaestro. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. International journal of antimicrobial agents. 2018 Nov; 52(5):643-650. doi: 10.1016/j.ijantimicag.2018.08.001. [PMID: 30103003]
  • Salmaan Kanji, Jason A Roberts, Jiao Xie, Abdulaziz Alobaid, Sheryl Zelenitsky, Swapnil Hiremath, Guijun Zhang, Irene Watpool, Rebecca Porteous, Rakesh Patel. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. The Annals of pharmacotherapy. 2018 10; 52(10):965-973. doi: 10.1177/1060028018773771. [PMID: 29730948]
  • Ronilda D'Cunha, Thanh Bach, Beth Ann Young, Peizhi Li, Demet Nalbant, Jun Zhang, Patricia Winokur, Guohua An. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. Antimicrobial agents and chemotherapy. 2018 09; 62(9):. doi: 10.1128/aac.00859-18. [PMID: 29941654]
  • Ronilda D'Cunha, Thanh Bach, Beth Ann Young, Peizhi Li, Demet Nalbant, Jun Zhang, Patricia Winokur, Guohua An. Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation. Antimicrobial agents and chemotherapy. 2018 09; 62(9):. doi: 10.1128/aac.00861-18. [PMID: 29941653]
  • Colin Bergstrom, Srikanth Nagalla, Arjun Gupta. Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam-Reply. JAMA internal medicine. 2018 08; 178(8):1137-1138. doi: 10.1001/jamainternmed.2018.2921. [PMID: 30083742]
  • Peter E Wu, Derek Leong. Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam. JAMA internal medicine. 2018 08; 178(8):1137. doi: 10.1001/jamainternmed.2018.2930. [PMID: 30083734]
  • Sylvia M Verhoven, Joseph J Groszek, William H Fissell, Adam Seegmiller, Jennifer Colby, Pratish Patel, Alain Verstraete, Matthew Shotwell. Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens. Clinica chimica acta; international journal of clinical chemistry. 2018 Jul; 482(?):60-64. doi: 10.1016/j.cca.2018.03.021. [PMID: 29596815]
  • Meritxell Royuela, Juliana Jaramillo, María Teresa Martín, Oscar Len. Skin infection in a renal transplant recipient. Medicina clinica. 2018 06; 150(11):454. doi: 10.1016/j.medcli.2017.07.028. [PMID: 29054576]
  • Mahipal G Sinnollareddy, Michael S Roberts, Jeffrey Lipman, Sandra L Peake, Jason A Roberts. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. The Journal of antimicrobial chemotherapy. 2018 06; 73(6):1647-1650. doi: 10.1093/jac/dky057. [PMID: 29506150]
  • Aiden J Plant, Alexander Dunn, Robert J Porter. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia. Expert review of anti-infective therapy. 2018 05; 16(5):367-368. doi: 10.1080/14787210.2018.1473079. [PMID: 29727213]
  • Zachary I Willis, Ravi Jhaveri. The Cost of Vancomycin and Piperacillin/Tazobactam Treatment. JAMA pediatrics. 2018 05; 172(5):494. doi: 10.1001/jamapediatrics.2018.0052. [PMID: 29507940]
  • Kevin J Downes, Benjamin L Laskin, Brian T Fisher. The Cost of Vancomycin and Piperacillin/Tazobactam Treatment-Reply. JAMA pediatrics. 2018 05; 172(5):494-495. doi: 10.1001/jamapediatrics.2018.0038. [PMID: 29507935]
  • Brian Yu, Adedayo Adedoyin, Ellie Hershberger, Luzelena Caro, Alan Xiao, Elizabeth G Rhee, Jennifer A Huntington. Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study. Clinical pharmacology in drug development. 2018 05; 7(4):382-391. doi: 10.1002/cpdd.429. [PMID: 29517862]
  • Mohammed A Alessa, Thamer A Almangour, Abdulaziz Alhossan, Musaed A Alkholief, Mohammed Alhokail, Deanne E Tabb. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018 May; 75(9):e184-e188. doi: 10.2146/ajhp170056. [PMID: 29691260]
  • Natalia D Popowicz, Sean J O'Halloran, Deirdre Fitzgerald, Y C Gary Lee, David A Joyce. A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Apr; 1081-1082(?):58-66. doi: 10.1016/j.jchromb.2018.02.027. [PMID: 29505960]
  • Carlos Ezquer-Garin, Rafael Ferriols-Lisart, Manuel Alós-Almiñana, Gerardo Aguilar-Aguilar, Javier F Belda-Nacher, Jose-Antonio Carbonell. Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma. Bioanalysis. 2018 Apr; 10(7):461-473. doi: 10.4155/bio-2017-0257. [PMID: 29633862]
  • Sofie A M Dhaese, Jason A Roberts, Mieke Carlier, Alain G Verstraete, Veronique Stove, Jan J De Waele. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. International journal of antimicrobial agents. 2018 Apr; 51(4):594-600. doi: 10.1016/j.ijantimicag.2017.12.015. [PMID: 29277531]
  • Shijie Wen, Changyuan Wang, Yingjie Duan, Xiaokui Huo, Qiang Meng, Zhihao Liu, Shilei Yang, Yanna Zhu, Huijun Sun, Xiaodong Ma, Siyun Yang, Kexin Liu. OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. International journal of pharmaceutics. 2018 Feb; 537(1-2):172-182. doi: 10.1016/j.ijpharm.2017.12.037. [PMID: 29277663]
  • Saiyuri Naicker, Yarmarly C Guerra Valero, Jenny L Ordenez Meija, Jeffrey Lipman, Jason A Roberts, Steven C Wallis, Suzanne L Parker. A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Journal of pharmaceutical and biomedical analysis. 2018 Jan; 148(?):324-333. doi: 10.1016/j.jpba.2017.10.023. [PMID: 29080413]
  • Sebastian Bischoff, Thomas Walter, Marlis Gerigk, Matthias Ebert, Roger Vogelmann. Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC infectious diseases. 2018 01; 18(1):56. doi: 10.1186/s12879-018-2960-9. [PMID: 29373965]
  • Matthew Rawlins, Vesa Cheng, Edward Raby, John Dyer, Adrian Regli, Paul Ingram, Brett C McWhinney, Jacobus P J Ungerer, Jason A Roberts. Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy. Chemotherapy. 2018; 63(4):203-206. doi: 10.1159/000493196. [PMID: 30304718]
  • Mariana Castanheira, Leonard R Duncan, Paul R Rhomberg, Helio S Sader. Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. Diagnostic microbiology and infectious disease. 2017 Dec; 89(4):305-309. doi: 10.1016/j.diagmicrobio.2017.08.011. [PMID: 28969934]
  • Marguerite L Monogue, Sean M Stainton, Arlinda Baummer-Carr, Ashley K Shepard, James F Nugent, Joseph L Kuti, David P Nicolau. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. Antimicrobial agents and chemotherapy. 2017 12; 61(12):. doi: 10.1128/aac.01449-17. [PMID: 28893779]
  • Elizabeth J Beckman. Piperacillin-Tazobactam Plus Vancomycin Equals Acute Kidney Injury: Does It Add Up?. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2017 12; 18(12):1183-1184. doi: 10.1097/pcc.0000000000001346. [PMID: 29206737]
  • Senthil Natesan, Manjunath P Pai, Thomas P Lodise. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. The Journal of antimicrobial chemotherapy. 2017 10; 72(10):2813-2816. doi: 10.1093/jac/dkx221. [PMID: 29091209]
  • Caleb W Anderson, Kathy S Cazares, Michael B Lustik, Shivam M Patel, Troy M Denunzio. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility. Military medicine. 2017 09; 182(9):e1773-e1778. doi: 10.7205/milmed-d-16-00197. [PMID: 28885936]
  • Imran Ali, Muhammad Shabbir. Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. JPMA. The Journal of the Pakistan Medical Association. 2017 Aug; 67(8):1161-1165. doi: NULL. [PMID: 28839298]
  • Farrin A Manian. Should We Revisit the Nephrotoxic Potential of Piperacillin-Tazobactam as Well?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 07; 65(1):178. doi: 10.1093/cid/cix321. [PMID: 28419199]
  • Jason M Pogue, Bhagyashri Navalkele, Keith S Kaye. Reply to Manian. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 07; 65(1):178-179. doi: 10.1093/cid/cix322. [PMID: 28419222]
  • Alexander R Shaw, Bruce A Mueller. Antibiotic Dosing in Continuous Renal Replacement Therapy. Advances in chronic kidney disease. 2017 07; 24(4):219-227. doi: 10.1053/j.ackd.2017.05.004. [PMID: 28778361]
  • Murat Dizbay, Hasan Selçuk Özger, Ömer Karaşahin, Emine Fusun Karaşahin. Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam. Turkish journal of medical sciences. 2016 Dec; 46(6):1760-1764. doi: 10.3906/sag-1506-157. [PMID: 28081324]
  • Anthony Aiudi, Benjamin Miller, Gopal Krishna, Adedayo Adedoyin, Alan Xiao. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects. Fundamental & clinical pharmacology. 2016 Dec; 30(6):625-633. doi: 10.1111/fcp.12227. [PMID: 27473285]
  • John J Veillette, S Alexander Winans, Steven C Forland, Victoria K Maskiewicz. A simple and rapid RP-HPLC method for the simultaneous determination of piperacillin and tazobactam in human plasma. Journal of pharmaceutical and biomedical analysis. 2016 Nov; 131(?):80-86. doi: 10.1016/j.jpba.2016.08.010. [PMID: 27529601]
  • Eliana S Armstrong, Janelle A Mikulca, Daniel J Cloutier, Caleb A Bliss, Judith N Steenbergen. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC infectious diseases. 2016 11; 16(1):710. doi: 10.1186/s12879-016-2057-2. [PMID: 27887579]
  • Joseph L Kuti, Islam M Ghazi, Richard Quintiliani, Eric Shore, David P Nicolau. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. International journal of antimicrobial agents. 2016 Sep; 48(3):342-3. doi: 10.1016/j.ijantimicag.2016.06.005. [PMID: 27451086]
  • Christina A Sutherland, David P Nicolau. Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. Journal of chromatographic science. 2016 Jul; 54(6):1037-40. doi: 10.1093/chromsci/bmw047. [PMID: 27048639]
  • Jennifer A Huntington, George Sakoulas, Obiamiwe Umeh, Daniel J Cloutier, Judith N Steenbergen, Caleb Bliss, Ellie J C Goldstein. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. The Journal of antimicrobial chemotherapy. 2016 07; 71(7):2014-21. doi: 10.1093/jac/dkw053. [PMID: 26994090]
  • Sirisha Kundrapu, Venkata C K Sunkesula, Lucy A Jury, Jennifer L Cadnum, Michelle M Nerandzic, Jackson S Musuuza, Ajay K Sethi, Curtis J Donskey. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?. BMC infectious diseases. 2016 Apr; 16(?):159. doi: 10.1186/s12879-016-1514-2. [PMID: 27091232]
  • Caroline Schneeberger, Frits Holleman, Suzanne E Geerlings. Febrile urinary tract infections: pyelonephritis and urosepsis. Current opinion in infectious diseases. 2016 Feb; 29(1):80-5. doi: 10.1097/qco.0000000000000227. [PMID: 26658652]